Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Christoph C. Eschenfelder"'
Autor:
Nils Kuklik, Anika Hüsing, Andreas Stang, Marcus Brinkmann, Christoph C. Eschenfelder, Christian Weimar, Hans-Christoph Diener
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundIntracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals wit
Externí odkaz:
https://doaj.org/article/6be94cdf4d414fee988ca644c63e58b6
Publikováno v:
Case Reports in Neurology, Vol 8, Iss 3, Pp 224-228 (2016)
Background and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case
Externí odkaz:
https://doaj.org/article/6531e081732f4efbb427188544d66cd8
Autor:
Christoph C. Eschenfelder, Anika Hüsing, Marcus Brinkmann, Christian Weimar, Andreas Stang, Gerrit M. Grosse, Hans-Christoph Diener, Nils Kuklik
Publikováno v:
European Stroke Journal. 6:438-444
Background The optimal timing of anticoagulation following acute ischaemic stroke or TIA in patients with atrial fibrillation (AF) is a frequent challenge. Early initiation of anticoagulation can reduce the risk for recurrent ischaemic events, but ma
Autor:
Sebastian Edelbusch, Christian H. Nolte, Olav Schwarte, Robert Wruck, Oliver Sauer, Gabriele Schackert, Yasser Abdalla, Valentin Held, Joachim Röther, Bettina von Sarnowksi, Claus G. Haase, Hans-Christoph Diener, Jan Latta, Rüdiger J. Seitz, Michael Daffertshofer, Silke Wunderlich, Karsten Witt, Torsten Rehfeldt, Eckhart Sindern, Peter Kühnlein, Elke Leinisch, Tobias Neumann-Haefelin, Raluca Rossi, Ulrich Pulkowski, Yogesh P Shah, Rolf Kern, Kristina Szabo, Lothar Burghaus, Peter D. Schellinger, Gebhard Becks, Martin Köhrmann, Mark Obermann, Ramona Schuppner, Christoph Leithner, Sebastian Senger, A. Lenz, Peer Patzschke, Jörg Berthel, Christoph C. Eschenfelder, Paul Sparenberg, Peter Kraft, Jan C. Purrucker, Albrecht Günther, Niklas Schäfer, Hazem El-Sabassy, Martin Grond, Rüdiger Gerlach, Karin Weissenborn, Sven Poli, Stefan Schwab, Thomas Kerz, Peter Wienecke, Carl-Albrecht Haensch, Peter A. Ringleb, Andreas Harloff, Felix J. Bode, Christian Urbanek, Pawel Kermer, Jürgen Eggers, Alexej Abraham, Maren Hieber, Joseph G Heckmann, Wolfgang Müllges, Thorsten Steiner, Someieh Partowi, Klaus Gröschel, Jörg Berrouschot, Florian Große-Dresselhaus, Hakan Cangür, Andreas Schneider, Andreas Kauert, Katharina Althaus, Mathias Mäurer
Publikováno v:
International journal of stroke 15(6), 609-618 (2020). doi:10.1177/1747493019895654
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for throm
Autor:
Bertram Boos, Michael Schneider, Patrick Baum, Petra Moroni-Zentgraf, Ralf Sigmund, Hanns Walter Müller, Egbert Mundt, Kimberley Kallsen, Christoph Keller, Mazyar Mahmoudi, Christoph C. Eschenfelder
To safeguard key workers involved in development and production of medicines and ensure business continuity, we developed an occupational healthcare program, performed by our company’s occupational healthcare services, to assess the infection and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b65bbbc0760a6e55a2068466bc97858
Publikováno v:
Stroke. 51
Recently we have shown that idarucizumab application in acute stroke patients treated with dabigatran improves clinical outcome parameters. In this retrospective series of 120 cases positive effects of dabigatran reversal could be documented regardin
Autor:
Moritz Armbrust, Reinhard Dengler, Martin Ebinger, Matthias Endres, Ralf Lichtinghagen, Christoph C. Eschenfelder, Helmut Schumacher, Hans Worthmann
Publikováno v:
Experimental and Clinical Endocrinology & Diabetes. 125:485-491
Reports on neuroprotective effects of Insulin-like growth factor-1 (IGF-1) and Insulin-like growth factor binding protein-3 (IGFBP-3) in ischemic brain tissue are inconsistent. The aim of this study was to determine if plasma levels of IGF-1 and IGFB
Publikováno v:
Stroke. 50
Reversal of anticoagulation in patients treated with NOACs is a rare but sometimes urgently needed therapeutic demand. Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes
Autor:
Martin Bendszus, Werner Hacke, Marc Fatar, Nils Wahlgren, Christoph C. Eschenfelder, Sven Poli, Christof Kessler, Geoffrey A. Donnan, Carlos A. Molina, Joaquín Serena, Peter A. Ringleb, Didier Leys, Peter D. Schellinger, Girish Muddegowda, Erich Bluhmki, Stefan Schwab, Danilo Toni
Background Intravenous thrombolysis with alteplase within a time window up to 4.5 h is the only approved pharmacological treatment for acute ischemic stroke. We studied whether acute ischemic stroke patients with penumbral tissue identified on magnet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c06e13f3424dce59fb14266feca9e912
http://hdl.handle.net/11573/1563539
http://hdl.handle.net/11573/1563539
Publikováno v:
The American journal of emergency medicine. 35(4)
Idarucizumab is an antibody fragment which is used to reverse the anticoagulant effects of dabigatran. We report on the first successful use of idarucizumab before performing an emergency lumbar puncture in a patient on effective anticoagulation with